Atopic Dermatitis (Atopic Eczema) Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Type (Corticosteroids, Calcineurin Inhibitors, Immunosuppressants, Phosphodiesterase Type 4 (PDE-4) Inhibitors, Antibiotics, Antihistamines, Emollients), By Route of Administration (Oral, Topical, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region

Atopic dermatitis treatment market size was valued at US$ 7,699.4 million in 2023 and is poised to grow at a CAGR of 9.2% during 2024-2030. The atopic eczema is a type of inflammatory disease that is of unknown origin and usually starts in early infancy, but also affects a major number of adults. Atopic dermatitis results in itchy, red, swollen, and cracked skin. Many people with atopic dermatitis may develop hay fever and asthma. The causes are unknown but it is found to involve inherited, immune system dysfunction, environmental exposure, and difficulties in the permeability of the skin. Multiple factors such as seasonal allergies, low humidity, exposure to harsh detergents & soaps, and cold weather can trigger or worsen atopic dermatitis, including. 

Furthermore, as per as a study published by the Indian Journal of Dermatology in August 2023, AD affects a significant portion of the global population, with 2–7% of adults and 10% of adults in high-income countries suffering from the condition. Among the pediatric population in high-income countries, the prevalence is around 20%. In India, reported prevalence ranges from 3.1% to 7.21% in children and up to 9.2% in combined pediatric and adult studies. The cost of medications and the associated economic burden are considerable, with mental health issues like depression and anxiety frequently reported alongside AD.

In addition, according to an article published by the Leo Foundation in October 2023, atopic dermatitis (AD) is the most common type of skin disease worldwide, affecting up to 20% of children and up to 10% of adults. Despite the progress made in treating severe forms of AD, the prevalence and severity of the disease pose significant challenges for individuals, families, and societies. The need for high-quality information on the prevalence and severity of AD, the Global Atopic Dermatitis Atlas has been established with a DKK 10 million grant from the LEO Foundation. This initiative aims to become a leading open resource, providing global and validated data on atopic dermatitis in one place.

In conclusion, the increasing prevalence of AD drives the demand for effective treatments. The rise in AD prevalence has expanded the market for atopic dermatitis treatments. Thus, this rise in prevalence underscores the growing need for effective treatments, fueling the demand and expansion of the atopic dermatitis market. As more people are diagnosed with AD, the market for therapies and management options is expected to grow, driving innovation and development in this field. Moreover, the global atopic dermatitis market is projected to reach US$ 5,307.5 Million by 2033 due to a combination of factors including a high prevalence of the condition, advanced healthcare infrastructure, and significant investment in dermatological research and development.

Key Developments:

• In April 2024, AbbVie launched RINVOQ (upadacitinib) demonstrated superiority over DUPIXENT (dupilumab) across primary and all secondary endpoints in the LEVEL UP study, a Phase 3b/4 head-to-head trial. This open-label, efficacy assessor-blinded study focused on adults and adolescents (≥12 years) with moderate-to-severe atopic dermatitis (AD) who had an inadequate response to systemic therapy or for whom such therapies were inadvisable.
• In October 2023, Bristol Myers Squibb and IMIDomics announced an expansion of their partnership to include Sjögren's syndrome and atopic dermatitis in their research and development efforts for immune-mediated inflammatory diseases. This collaboration aims to advance therapeutic options and improve outcomes for patients affected by these conditions, as stated in their joint press release.

The list of pharmaceutical companies, the products they offer for the treatment of atopic dermatitis, and the year of launch.

Sanofi: Dupixent (Dupilumab) - Launched in 2017.

Regeneron Pharmaceuticals: Dupixent (Dupilumab) - Launched in 2017.

Pfizer: Eucrisa (Crisaborole) - Launched in 2016.

Eli Lilly: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021.

Incyte Corporation: Olumiant (Baricitinib) - Initially approved for rheumatoid arthritis in 2018, and received FDA approval for atopic dermatitis in 2021